Treatment for central centrifugal cicatricial alopecia-Delphi consensus recommendations
- PMID: 38341148
- DOI: 10.1016/j.jaad.2023.12.073
Treatment for central centrifugal cicatricial alopecia-Delphi consensus recommendations
Abstract
Background: There is no established standard of care for treating central centrifugal cicatricial alopecia (CCCA), and treatment approaches vary widely.
Objective: To develop consensus statements regarding the use of various pharmacological therapies in treating adults with CCCA.
Methods: We invited 27 dermatologists with expertise in hair and scalp disorders to participate in a 3-round modified Delphi study between January and March 2023. Statements met strong consensus if 75% of respondents agreed or disagreed. Statements met moderate consensus if 55% or more but less than 75% agreed or disagreed.
Results: In round 1, 5 of 33 (15.2%) statements met strong consensus, followed by 9 of 28 (32.1%) in round 2. After the final round 3 meeting, strong consensus was reached for 20 of 70 (28.6%) overall statements. Two statements achieved moderate consensus.
Limitations: This study included only English-speaking, US-based dermatologists and did not consider nonpharmacological therapies.
Conclusion: Despite varying opinions among dermatologists, consensus was reached for several statements to help clinicians manage CCCA. We also highlight areas that lack expert consensus with the goal of advancing research and therapeutic options for CCCA.
Keywords: CCCA; alopecia; central centrifugal cicatricial alopecia; cicatricial alopecia; consensus; delphi; dermatology; guidelines; hair loss; modified delphi; recommendation; scarring alopecia; therapy; treatment.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Conflicts of interest Dr Barbosa has served as a consultant or advisory board member to the following companies in the last 2 years: Eli Lilly, Pfizer, UCB, and Vichy. Dr Harvey has served as a consultant or advisory board member for Eli Lilly, Skinceuticals, Janssen, L’Oréal, Unilever, Pfizer, and Abbvie. Dr Mayo has served as an investigator or consultant for Arcutis, Acelyrin, BMS, ChemoCentryx, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pfizer, and Procter & Gamble. Dr McMichael has grants/research or consulting relationships with Concert, Procter & Gamble, Incyte, Eli Lilly, Janssen, Pfizer, Arcutis, Almirall, AbbVie, Galderma, Bristol Meyers Squibb, Sanofi-Genzyme, UCB, Revian, Johnson & Johnson, L'oreal, and Leo. Dr Piliang has relationships with Eli Lilly and Company, Pfizer Inc, and Procter & Gamble Company. Dr Tosti is consultant for DS Laboratories, Monat Global, Almirall, Tirthy Madison, Eli Lilly, P&G, Pfizer, Myovant, Bristol Myers Squibb, Ortho Dermatologics, Curallux LLC and PI for Eli Lilly, Concert. Dr Frey has served as a consultant or advisor for the following: Procter & Gamble, Sun Pharma, Galderma, CeraVe, La Roche Posay, Regeneron, Avita, and Ferndale. Dr Adotama has served as a consultant or advisory board member for Sanofi Regeneron, Janssen, Bristol-Myers, and Argenx. Dr Taylor has served as a consultant, advisory board member, and/or speaker for AbbVie, Arcutis, Armis Scientific, Avita, Beiersdorf, Biorez, Bristol-Myers Squibb, Cara Therapeutics, Dior, Eli Lilly, EPI Health, Evolus, Galderma, GloGetter, Hugel America, Incyte, Johnson & Johnson, L'Oreal USA, MedScape, MJH LifeSciences, Pfizer, Piction Health, Sanofi, Scientis US, UCB, and Vichy Laboratoires. She has received royalties from McGraw-Hill. She has served as an investigator for Allergan, Concert Pharmaceuticals/Sun Pharma, Croma-Pharma GmbH, Eli Lilly, and Pfizer. Authors Jackson, Sow, Dinkins, Drs Aguh, Ayoade, Burgess, Callender, Cotsarelis, Grimes, Kindred, Lester, Sicco, Oboite, Ogunleye, Olsen, Osei-Tutu, and Shapiro have no conflicts of interest to declare.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
